

Colin L Masters

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8651950/colin-l-masters-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

502
papers

42,503
citations

94
h-index

196
g-index

567
ext. papers

49,001
ext. citations

7.5
avg, IF

6.94
L-index

#	Paper	IF	Citations
502	Analysis of plasma proteins using 2D gels and novel fluorescent probes: in search of blood based biomarkers for Alzheimer's disease.. <i>Proteome Science</i> , 2022 , 20, 2	2.6	1
501	APOE ϵ resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2	2
500	Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2	2
499	Plasma microRNA vary in association with the progression of Alzheimer's disease.. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022 , 14, e12251	5.2	2
498	Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum.. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022 , 14, e12307	5.2	2
497	Cerebrospinal fluid Alzheimer disease biomarkers for assessing cognitive and neuropsychiatric symptoms: Expanding the 'toolkit' in the psychiatrist's diagnostic armamentarium.. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022 , 48674221084245	2.6	0
496	The Association Between Alzheimer's Disease-Related Markers and Physical Activity in Cognitively Normal Older Adults.. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14, 771214	5.3	1
495	Mesial temporal tau in amyloid-negative cognitively normal older persons.. <i>Alzheimer's Research and Therapy</i> , 2022 , 14, 51	9	1
494	Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer's disease.. <i>Science Advances</i> , 2022 , 8, eabm5667	14.3	0
493	Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF A β 2 moderates the association between insulin resistance and increased CSF tau levels.. <i>Neurobiology of Aging</i> , 2022 , 114, 38-48	5.6	0
492	Enhanced ion mobility resolution of A β isomers from human brain using high-resolution demultiplexing software.. <i>Analytical and Bioanalytical Chemistry</i> , 2022 , 1	4.4	1
491	Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume.. <i>GeroScience</i> , 2022 , 1	8.9	1
490	Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study. <i>Biomedicine</i> , 2022 , 10, 1045	4.8	1
489	Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid- β <i>Neurobiology of Disease</i> , 2022 , 105783	7.5	1
488	Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives.. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021 , 48674211058684	2.6	1
487	Effects of a physical activity intervention on brain atrophy in older adults at risk of dementia: a randomized controlled trial. <i>Brain Imaging and Behavior</i> , 2021 , 1	4.1	
486	A Paradox in Digital Memory Assessment: Increased Sensitivity With Reduced Difficulty. <i>Frontiers in Digital Health</i> , 2021 , 3, 780303	2.3	0

485	Higher Coffee Consumption Is Associated With Slower Cognitive Decline and Less Cerebral Aβ Amyloid Accumulation Over 126 Months: Data From the Australian Imaging, Biomarkers, and Lifestyle Study. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 744872	5.3	5
484	A deep learning framework identifies dimensional representations of Alzheimer's Disease from brain structure. <i>Nature Communications</i> , 2021 , 12, 7065	17.4	2
483	A six-metabolite panel as potential blood-based biomarkers for Parkinson's disease. <i>Npj Parkinsons Disease</i> , 2021 , 7, 94	9.7	0
482	Genomics of Alzheimer's disease implicates the innate and adaptive immune systems. <i>Cellular and Molecular Life Sciences</i> , 2021 , 78, 7397-7426	10.3	4
481	Association of Aβ Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals. <i>Neurology</i> , 2021 , 96, e662-e670	6.5	10
480	Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
479	Genetic testing in dementia-A medical genetics perspective. <i>International Journal of Geriatric Psychiatry</i> , 2021 , 36, 1158-1170	3.9	2
478	Quantification of N-terminal amyloid-β isoforms reveals isomers are the most abundant form of the amyloid-β peptide in sporadic Alzheimer's disease. <i>Brain Communications</i> , 2021 , 3, fcab028	4.5	6
477	Relevance of a Truncated PRESENILIN 2 Transcript to Alzheimer's Disease and Neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2021 , 80, 1479-1489	4.3	0
476	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. <i>Brain Connectivity</i> , 2021 , 11, 239-249	2.7	5
475	Core Alzheimer's disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 79	9	
474	Undetected Neurodegenerative Disease Biases Estimates of Cognitive Change in Older Adults. <i>Psychological Science</i> , 2021 , 32, 849-860	7.9	2
473	Bundle-specific associations between white matter microstructure and Aβ and tau pathology in preclinical Alzheimer's disease. <i>ELife</i> , 2021 , 10,	8.9	3
472	Characterization of brain-derived extracellular vesicle lipids in Alzheimer's disease. <i>Journal of Extracellular Vesicles</i> , 2021 , 10, e12089	16.4	10
471	Androgen receptor CAG repeat length as a moderator of the relationship between free testosterone levels and cognition. <i>Hormones and Behavior</i> , 2021 , 131, 104966	3.7	1
470	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2021 , 5, 443-468	3.3	15
469	Longitudinal Trajectories in Cortical Thickness and Volume Atrophy: Superior Cognitive Performance Does Not Protect Against Brain Atrophy in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2021 , 81, 1039-1052	4.3	
468	Deaths with Dementia in Indigenous and Non-Indigenous Australians: A Nationwide Study. <i>Journal of Alzheimer's Disease</i> , 2021 , 81, 1589-1599	4.3	2

467	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021 , 27, 1187-1196	50.5	51
466	Comparing amyloid- β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. <i>Acta Neuropathologica</i> , 2021 , 142, 689-706	14.3	8
465	The BDNF SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021 , 26, 614-628	15.1	34
464	Aggregation of Abnormal Memory Scores and Risk of Incident Alzheimer's Disease Dementia: A Measure of Objective Memory Impairment in Amnesic Mild Cognitive Impairment. <i>Journal of the International Neuropsychological Society</i> , 2021 , 27, 146-157	3.1	3
463	Polygenic score modifies risk for Alzheimer's disease in β homozygotes at phenotypic extremes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12226	5.2	0
462	Learning deficit in cognitively normal APOE β carriers with LOW β amyloid. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12136	5.2	2
461	Presymptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy-Related Blood Metabolite Alterations. <i>Journal of Alzheimer's Disease</i> , 2021 , 79, 895-903	4.3	1
460	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12197	5.2	
459	Association of naturally occurring antibodies to β amyloid with cognitive decline and cerebral amyloidosis in Alzheimer's disease. <i>Science Advances</i> , 2021 , 7,	14.3	8
458	BDNF VAL66MET polymorphism and memory decline across the spectrum of Alzheimer's disease. <i>Genes, Brain and Behavior</i> , 2021 , 20, e12724	3.6	6
457	Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies. <i>NeuroImage</i> , 2021 , 226, 117593	7.9	3
456	Visual Memory Deficits in Middle-Aged APOE ϵ 4 Homozygotes Detected Using Unsupervised Cognitive Assessments. <i>Journal of Alzheimer's Disease</i> , 2021 , 79, 1563-1573	4.3	2
455	Is Associated with Amyloid- β and β -Related Cognitive Decline in Cognitively Normal Adults. <i>Journal of Alzheimer's Disease Reports</i> , 2021 , 5, 111-120	3.3	1
454	Deficits in Monocyte Function in Age Related Macular Degeneration: A Novel Systemic Change Associated With the Disease. <i>Frontiers in Medicine</i> , 2021 , 8, 634177	4.9	3
453	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. <i>Lancet Neurology</i> , 2021 , 20, 615-626	24.1	11
452	The Amyloid- β Pathway in Alzheimer's Disease. <i>Molecular Psychiatry</i> , 2021 ,	15.1	63
451	Deep Generative Medical Image Harmonization for Improving Cross-Site Generalization in Deep Learning Predictors. <i>Journal of Magnetic Resonance Imaging</i> , 2021 ,	5.6	3
450	Citrullination of Amyloid- β Peptides in Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2021 , 12, 3719-3737	3.7	2

449	Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	11
448	Modeling autosomal dominant Alzheimer's disease with machine learning. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1005-1016	1.2	5
447	Relationship between amyloid and tau levels and its impact on tau spreading. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2225-2232	8.8	8
446	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , 2021 , 96, e1632-e1645	6.5	4
445	Using imputation to provide harmonized longitudinal measures of cognition across AIBL and ADNI. <i>Scientific Reports</i> , 2021 , 11, 23788	4.9	3
444	Validation of Plasma Amyloid- β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.. <i>Neurology</i> , 2021 ,	6.5	7
443	The anti-amyloid treatment in asymptomatic Alzheimer's disease (A4) study: Report of screening and recruitment characteristics of the Melbourne composite site. <i>Alzheimer's and Dementia</i> , 2020 , 16, e042786	1.2	
442	Risk factors for falls in preclinical and prodromal Alzheimer's disease and dementia due to Alzheimer's disease: Findings from the Australian Imaging, Biomarker and Lifestyle study of ageing (AIBL). <i>Alzheimer's and Dementia</i> , 2020 , 16, e044954	1.2	
441	The function and composition of brain tissue derived exosomes in human Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045561	1.2	
440	Relationship of Established Cardiovascular Risk Factors and Peripheral Biomarkers on Cognitive Function in Adults at Risk of Cognitive Deterioration. <i>Journal of Alzheimer's Disease</i> , 2020 , 74, 163-171	4.3	6
439	Small RNA fingerprinting of Alzheimer's disease frontal cortex extracellular vesicles and their comparison with peripheral extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2020 , 9, 1766822	16.4	24
438	Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19. <i>Journal of Alzheimer's Disease</i> , 2020 , 76, 27-31	4.3	5
437	Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 76, 303-315	4.3	7
436	Plasma transferrin and hemopexin are associated with altered A β uptake and cognitive decline in Alzheimer's disease pathology. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 72	9	8
435	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2020 , 26, 398-407	50.5	160
434	Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12005	5.2	17
433	Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 22	9	39
432	MRI signatures of brain age and disease over the lifespan based on a deep brain network and 14 468 individuals worldwide. <i>Brain</i> , 2020 , 143, 2312-2324	11.2	58

431	Optimizing red blood cell protein extraction for biomarker quantitation with mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2020 , 412, 1879-1892	4.4	3
430	Baseline White Matter Is Associated With Physical Fitness Change in Preclinical Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020 , 12, 115	5.3	4
429	Total A β ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis. <i>Neurology</i> , 2020 , 94, e1580-e1591	6.5	38
428	Comorbidity of Cerebrovascular and Alzheimer's Disease in Aging. <i>Journal of Alzheimer's Disease</i> , 2020 , 78, 321-334	4.3	2
427	Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-A β load and cerebrospinal fluid A β in a pilot study of Alzheimer's disease. <i>Neuroscience Letters</i> , 2020 , 731, 135078	3.3	1
426	Major risk factors for Alzheimer's disease: age and genetics. <i>Lancet Neurology</i> , 2020 , 19, 475-476	24.1	5
425	Autosomal Dominantly Inherited Alzheimer Disease: Analysis of genetic subgroups by Machine Learning. <i>Information Fusion</i> , 2020 , 58, 153-167	16.7	8
424	Cerebrospinal fluid neurofilament light chain is elevated in Niemann-Pick type C compared to psychiatric disorders and healthy controls and may be a marker of treatment response. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020 , 54, 648-649	2.6	10
423	Harmonization of large MRI datasets for the analysis of brain imaging patterns throughout the lifespan. <i>NeuroImage</i> , 2020 , 208, 116450	7.9	79
422	Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. <i>Alzheimer's and Dementia</i> , 2020 , 16, 552-560	1.2	33
421	Influence of Comorbidity of Cerebrovascular Disease and Amyloid- β on Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 73, 897-907	4.3	12
420	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. <i>Brain Communications</i> , 2020 , 2, fcaa102	4.5	6
419	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. <i>NeuroImage: Clinical</i> , 2020 , 28, 102491	5.3	4
418	Intra-cerebral haemorrhage but not neurodegenerative disease appears over-represented in deaths of Australian cadaveric pituitary hormone recipients. <i>Journal of Clinical Neuroscience</i> , 2020 , 81, 78-82	2.2	1
417	Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer's disease. <i>Nature Communications</i> , 2020 , 11, 5698	17.4	23
416	Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study. <i>Neurology</i> , 2020 , 95, e3104-e3116	6.5	13
415	Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimer's Disease Patients and Correlates with Cognitive Performance. <i>Journal of Alzheimer's Disease</i> , 2020 , 77, 733-744	4.3	3
414	Association of deficits in short-term learning and A β and hippocampal volume in cognitively normal adults. <i>Neurology</i> , 2020 , 95, e2577-e2585	6.5	18

413	Longitudinal evaluation of the natural history of amyloid- β in plasma and brain. <i>Brain Communications</i> , 2020 , 2, fcaa041	4.5	6
412	Plasma Amyloid- β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 77, 1057-1065	4.3	14
411	Morphometric Changes to Corneal Dendritic Cells in Individuals With Mild Cognitive Impairment. <i>Frontiers in Neuroscience</i> , 2020 , 14, 556137	5.1	9
410	A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A 'C-reactive protein' for psychiatrists and neurologists?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020 , 54, 57-67	2.6	18
409	Effect of a 24-month physical activity program on brain changes in older adults at risk of Alzheimer's disease: the AIBL active trial. <i>Neurobiology of Aging</i> , 2020 , 89, 132-141	5.6	15
408	Increased cerebral blood flow with increased amyloid burden in the preclinical phase of Alzheimer's disease. <i>Journal of Magnetic Resonance Imaging</i> , 2020 , 51, 505-513	5.6	20
407	Use of an experimental language acquisition paradigm for standardized neuropsychological assessment of learning: A pilot study in young and older adults. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2020 , 42, 55-65	2.1	7
406	Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 36	9	16
405	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine-learning. <i>Alzheimer's and Dementia</i> , 2020 , 16, 501-511	1.2	20
404	Genetic resilience to Alzheimer's disease in APOE ϵ homozygotes: A systematic review. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1612-1623	1.2	12
403	A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1448-1457	1.2	3
402	Rates of age- and amyloid β -associated cortical atrophy in older adults with superior memory performance. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 566-575 ^{5.2}	5.2	12
401	Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease. <i>Nature Communications</i> , 2019 , 10, 4227	17.4	77
400	Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 670-678	5.2	7
399	Characterization of the metal status of natively purified alpha-synuclein from human blood, brain tissue, or recombinant sources using size exclusion ICP-MS reveals no significant binding of Cu, Fe or Zn. <i>Metallomics</i> , 2019 , 11, 128-140	4.5	9
398	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. <i>Nature Medicine</i> , 2019 , 25, 277-283	50.5	375
397	Klotho allele status is not associated with A β and APOE ϵ -related cognitive decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019 , 76, 162-165	5.6	19
396	Method comparison study of the Elecsys β -Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS. <i>Clinical Biochemistry</i> , 2019 , 72, 7-14	3.5	18

395	Avoiding methodological bias in studies of amyloid imaging results disclosure. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 52	9	3
394	Comparison of F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL approaches: Validation against histopathology. <i>Alzheimer's and Dementia</i> , 2019 , 15, 807-816	1.2	26
393	val158met is not associated with A β amyloid and β related cognitive decline in cognitively normal older adults. <i>IBRO Reports</i> , 2019 , 6, 147-152	2	4
392	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2019 , 142, 1429-1440	11.2	22
391	ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. <i>Neurology</i> , 2019 , 92, e1567-e1579	6.5	40
390	To What Extent Does Age at Death Account for Sex Differences in Rates of Mortality From Alzheimer Disease?. <i>American Journal of Epidemiology</i> , 2019 , 188, 1213-1223	3.8	16
389	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 180-190	5.2	46
388	Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2019 , 41, 591-600	2.1	8
387	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. <i>Science Advances</i> , 2019 , 5, eaau7220	14.3	44
386	Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β Associated Cognitive Decline in Older Adults. <i>Archives of Clinical Neuropsychology</i> , 2019 , 34, 585-598	2.7	11
385	Determining clinically meaningful decline in preclinical Alzheimer disease. <i>Neurology</i> , 2019 , 93, e322-e333	3.5	40
384	The dawn of robust individualised risk models for dementia. <i>Lancet Neurology</i> , 2019 , 18, 985-987	24.1	3
383	Visual paired associate learning deficits associated with elevated beta-amyloid in cognitively normal older adults. <i>Neuropsychology</i> , 2019 , 33, 964-974	3.8	11
382	Decrease in p3-Alc β 7 and p3-Alc β 40, products of Alcadin β generated by β secretase cleavages, in aged monkeys and patients with Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 740-750	6	1
381	IC-P-167: AUTOMATED REPORTING OF TAU PET QUANTIFICATION ON BRAIN SURFACE 2019 , 15, P131-P132		1
380	IC-P-004: CORRECTING FOR PET SCANNER CHANGES IN LONGITUDINAL STUDIES 2019 , 15, P15-P15		
379	IC-P-017: AMYLOID PET IS MORE THAN JUST POSITIVE OR NEGATIVE: AMYLOID LEVEL IMPACTS RISK OF CLINICAL PROGRESSION IN NORMAL INDIVIDUALS 2019 , 15, P26-P27		
378	Validation of a priori candidate Alzheimer's disease SNPs with brain amyloid-beta deposition. <i>Scientific Reports</i> , 2019 , 9, 17069	4.9	9

377	An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. <i>Nature Neuroscience</i> , 2019 , 22, 1903-1912	25.5	118
376	A Randomized Controlled Trial of Adherence to a 24-Month Home-Based Physical Activity Program and the Health Benefits for Older Adults at Risk of Alzheimer's Disease: The AIBL Active-Study. <i>Journal of Alzheimer's Disease</i> , 2019 , 70, S187-S205	4.3	7
375	Seizures as an early symptom of autosomal dominant Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019 , 76, 18-23	5.6	19
374	Multisite study of the relationships between antemortem [C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2019 , 15, 205-216	12.6	82
373	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. <i>Brain</i> , 2018 , 141, 1186-1200	11.2	54
372	Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ amyloid burden. <i>Translational Psychiatry</i> , 2018 , 8, 47	8.6	59
371	Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. <i>Brain</i> , 2018 , 141, 1486-1500	11.2	46
370	Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer's disease. <i>Personalized Medicine in Psychiatry</i> , 2018 , 7-8, 14-20	1.1	8
369	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. <i>Lancet Neurology</i> , 2018 , 17, 241-250	24.1	224
368	Associations of Dietary Protein and Fiber Intake with Brain and Blood Amyloid-β. <i>Journal of Alzheimer's Disease</i> , 2018 , 61, 1589-1598	4.3	21
367	Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. <i>Nature Reviews Neurology</i> , 2018 , 14, 225-236	15	211
366	High performance plasma amyloid-β biomarkers for Alzheimer's disease. <i>Nature</i> , 2018 , 554, 249-254	50.4	733
365	KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ amyloid burden. <i>Scientific Reports</i> , 2018 , 8, 2034	4.9	21
364	Association of Aβ Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2018 , 75, 488-494	17.2	51
363	Amyloid burden and incident depressive symptoms in preclinical Alzheimer's disease. <i>Journal of Affective Disorders</i> , 2018 , 229, 269-274	6.6	15
362	Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 965-992	4.3	57
361	Baseline Amnesic Severity Predicts Progression From Amnesic Mild Cognitive Impairment to Alzheimer Disease Dementia at 3 Years. <i>Alzheimer Disease and Associated Disorders</i> , 2018 , 32, 190-196	2.5	14
360	CSF Tau supplements 14-3-3 protein detection for sporadic Creutzfeldt-Jakob disease diagnosis while transitioning to next generation diagnostics. <i>Journal of Clinical Neuroscience</i> , 2018 , 50, 292-293	2.2	6

359	Trajectories of depressive and anxiety symptoms in older adults: a 6-year prospective cohort study. <i>International Journal of Geriatric Psychiatry</i> , 2018 , 33, 405-413	3.9	13
358	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: Aβ serial magnetic resonance imaging study. <i>Alzheimer's and Dementia</i> , 2018 , 14, 43-53	1.2	28
357	Ocular Biomarkers of Alzheimer's Disease: The Role of Anterior Eye and Potential Future Directions 2018 , 59, 3554-3563		15
356	Effect of BDNF Val66Met on disease markers in dominantly inherited Alzheimer's disease. <i>Annals of Neurology</i> , 2018 , 84, 424-435	9.4	14
355	The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults. <i>Intelligence</i> , 2018 , 70, 22-29	3	8
354	Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018 , 65, 977-988	4.3	13
353	Implementing the centiloid transformation for C-PiB and β amyloid F-PET tracers using CapAIBL. <i>NeuroImage</i> , 2018 , 183, 387-393	7.9	47
352	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. <i>PLoS ONE</i> , 2018 , 13, e0195838	3.7	34
351	Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018 , 70, 170-179	5.6	10
350	Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms. <i>Journal of Alzheimer's Disease</i> , 2018 , 61, 169-183	4.3	16
349	Trajectories of irregular word reading ability as a proxy for premorbid intelligence in Alzheimer's disease, mild cognitive impairment, and healthy aging: A longitudinal study. <i>Psychological Assessment</i> , 2018 , 30, 1308-1316	5.3	4
348	P2-364: TAU IMAGING IN ALZHEIMER'S DISEASE WITH [F-18]-MK6240, A SECOND GENERATION SELECTIVE TAU TRACER 2018 , 14, P831-P832		
347	IC-P-223: TO TAU OR TO MAO-B? MOST OF THE [F-18]-THK5351 SIGNAL IS BLOCKED BY SELEGILINE 2018 , 14, P181-P182		
346	P1-405: VISUAL ASSESSMENT OF β AMYLOID PET SCAN IS IMPROVED BY CAPAIBL 2018 , 14, P459-P459		
345	O4-09-01: COMPARISON OF THE NATURAL HISTORY OF NEOCORTICAL β AMYLOID, HIPPOCAMPAL VOLUME AND PACC IN SPORADIC AD 2018 , 14, P1423-P1424		
344	P3-494: EXAMINING THE INFLUENCE OF UNDETECTED ATN NEUROPATHOLOGY ON COGNITIVE AGING TRAJECTORIES 2018 , 14, P1311-P1311		
343	P3-620: INCREASED PROTEIN AND FIBRE INTAKE IS ASSOCIATED WITH HIGHER PERFORMANCE IN THE AIBL PACC SCORE IN COGNITIVELY NORMAL ADULTS: AUSTRALIAN IMAGING, BIOMARKERS AND LIFESTYLE (AIBL) STUDY 2018 , 14, P1368-P1369		
342	O1-04-01: PRECLINICAL ALZHEIMER'S DISEASE IS ASSOCIATED WITH LEARNING IMPAIRMENTS OVER SIX DAYS: RESULTS FROM THE ONLINE REPEATED COGNITIVE ASSESSMENT (ORCA) STUDY 2018 , 14, P223-P223		

341	O2-15-03: DIFFERENTIAL RISK FACTORS FOR PROGRESSION TO MCI/DEMENTIA BY AMYLOID-BETA STATUS 2018 , 14, P661-P661		
340	P1-440: INCREASED CEREBRAL BLOOD FLOW WITH INCREASED AMYLOID BURDEN IN PRECLINICAL AD 2018 , 14, P479-P480		
339	IC-P-008: VISUAL ASSESSMENT OF β AMYLOID PET SCAN IS IMPROVED BY CAPAIBL 2018 , 14, P18-P19		
338	P1-006: EXAMINING THE RESILIENCE OF SUPERAGERS: RISK OF CLINICAL PROGRESSION AND β ASSOCIATED MEMORY DECLINE OVER 8 YEARS 2018 , 14, P264-P264		
337	Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. <i>Journal of Alzheimer's Disease</i> , 2018 , 66, 1193-1211	4.3	16
336	CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	41
335	A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 423	5.3	11
334	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. <i>Nature Reviews Neurology</i> , 2018 , 14, 639-652	15	257
333	A Framework to Objectively Identify Reference Regions for Normalizing Quantitative Imaging. <i>Lecture Notes in Computer Science</i> , 2018 , 65-72	0.9	1
332	White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2018 , 141, 3065-3080	11.2	72
331	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1427-1437	1.2	31
330	Mediterranean diet adherence and rate of cerebral β amyloid accumulation: Data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. <i>Translational Psychiatry</i> , 2018 , 8, 238	8.6	29
329	Relationship Between Amyloid- β Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2018 , 65, 1313-1325	4.3	14
328	Sex, amyloid, and APOE ϵ 4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1193-1203	1.2	111
327	Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography. <i>Journal of Alzheimer's Disease</i> , 2018 , 63, 1299-1305	4.3	16
326	Amyloid burden and incident depressive symptoms in cognitively normal older adults. <i>International Journal of Geriatric Psychiatry</i> , 2017 , 32, 455-463	3.9	36
325	Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 56, 441-446	4.3	9
324	Cognitive impairment and decline in cognitively normal older adults with high amyloid- β A meta-analysis. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 6, 108-121	5.2	96

323	Selenium Levels in Serum, Red Blood Cells, and Cerebrospinal Fluid of Alzheimer's Disease Patients: A Report from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL). <i>Journal of Alzheimer's Disease</i> , 2017 , 57, 183-193	4.3	38
322	APOEε4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017 , 57, 411-422	4.3	9
321	Plasma Amyloid-β Peptides in Type 2 Diabetes: A Matched Case-Control Study. <i>Journal of Alzheimer's Disease</i> , 2017 , 56, 1127-1133	4.3	8
320	Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017 , 13, 1197-1206	1.2	32
319	The APOE ε4 Allele Is Associated with Lower Selenium Levels in the Brain: Implications for Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2017 , 8, 1459-1464	5.7	35
318	Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 8, 60-72	5.2	17
317	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. <i>Scientific Reports</i> , 2017 , 7, 1225	4.9	32
316	Characterization and Identification of Dityrosine Cross-Linked Peptides Using Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2017 , 89, 6136-6145	7.8	53
315	Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals. <i>Journal of Alzheimer's Disease</i> , 2017 , 58, 1293-1302	4.3	25
314	A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: The preclinical AD consortium. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 8, 147-155	5.2	15
313	Biochemically-defined pools of amyloid-β in sporadic Alzheimer's disease: correlation with amyloid PET. <i>Brain</i> , 2017 , 140, 1486-1498	11.2	70
312	Increased Carbohydrate Intake is Associated with Poorer Performance in Verbal Memory and Attention in an APOE Genotype-Dependent Manner. <i>Journal of Alzheimer's Disease</i> , 2017 , 58, 193-201	4.3	9
311	Using Robust Normative Data to Investigate the Neuropsychology of Cognitive Aging. <i>Archives of Clinical Neuropsychology</i> , 2017 , 32, 142-154	2.7	39
310	A systemic view of Alzheimer disease - insights from amyloid-β metabolism beyond the brain. <i>Nature Reviews Neurology</i> , 2017 , 13, 612-623	15	356
309	Plasma amyloid β42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 8, 179-187	5.2	82
308	A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β amyloid load in an AD cohort. <i>Scientific Reports</i> , 2017 , 7, 14057	4.9	15
307	Evaluation of Cholinergic Deficiency in Preclinical Alzheimer's Disease Using Pupillometry. <i>Journal of Ophthalmology</i> , 2017 , 2017, 7935406	2	17
306	A Multi-Cohort Study of ApoE ε4 and Amyloid-β Effects on the Hippocampus in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 56, 1159-1174	4.3	25

305	Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. <i>Scientific Reports</i> , 2017 , 7, 9766	4.9	38
304	BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF. <i>International Psychogeriatrics</i> , 2017 , 29, 1825-1834	3.4	14
303	A rigorous method to enrich for exosomes from brain tissue. <i>Journal of Extracellular Vesicles</i> , 2017 , 6, 1348885	16.4	113
302	[O30901]: IMPLEMENTING THE CENTILOID TRANSFORMATION FOR 18F-FLORBETABEN AND 18F-NAV4694 USING CAPABL 2017 , 13, P920		1
301	A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017 , 3, 622-635	6	51
300	[P1007]: SELF-REPORTED PHYSICAL ACTIVITY IS ASSOCIATED WITH TAU BURDEN AS MEASURED BY PET 2017 , 13, P528-P528		
299	2017 ,		1
298	F-Florbetaben PET beta-amyloid binding expressed in Centiloids. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 2053-2059	8.8	55
297	Amyloid β associated cognitive decline in the absence of clinical disease progression and systemic illness. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 8, 156-164	5.2	15
296	The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2017 , 5, 53	7.3	57
295	Associations of neighborhood environment with brain imaging outcomes in the Australian Imaging, Biomarkers and Lifestyle cohort. <i>Alzheimer's and Dementia</i> , 2017 , 13, 388-398	1.2	15
294	β Amyloid and Tau Imaging in Dementia. <i>Seminars in Nuclear Medicine</i> , 2017 , 47, 75-88	5.4	72
293	Plasma Cortisol, Brain Amyloid- β and Cognitive Decline in Preclinical Alzheimer's Disease: A 6-Year Prospective Cohort Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2017 , 2, 45-52 ^{3,4}	3.4	22
292	[P2035]: DIFFERENCES IN LONGEVITY AND DEATH CERTIFICATION ACCOUNT FOR SEX DISPARITY IN DEMENTIA MORTALITY RATES 2017 , 13, P847-P848		
291	[P3024]: THE INFLUENCE OF LOW-DENSITY LIPOPROTEINS ON NEOCORTICAL AMYLOID LOAD IN THE AUSTRALIAN IMAGING BIOMARKER AND LIFESTYLE STUDY 2017 , 13, P1023-P1024		
290	[P3043]: A MASS SPECTROMETRY-BASED DISCOVERY AND REPLICATION OF A MULTI-ANALYTE CLASSIFIER FOR NEOCORTICAL AMYLOID PATHOLOGY 2017 , 13, P1033-P1033		
289	[P3062]: CONSIDERATION OF PRECLINICAL AD FROM THE PERSPECTIVE OF NORMAL AGING: AMYLOID- β RELATED CHANGES IN FLUID AND CRYSTALLIZED INTELLIGENCE IN A ROBUST SAMPLE OF HEALTHY OLDER ADULTS 2017 , 13, P1150-P1150		
288	[P4034]: INSULIN RESISTANCE IS ASSOCIATED WITH REDUCTIONS IN SPECIFIC COGNITIVE DOMAINS AND INCREASES IN CSF TAU IN COGNITIVELY NORMAL ADULTS 2017 , 13, P1308-P1308		

287	[P1136]: IL-10 AND IL-12/23P40 ARE JOINTLY ASSOCIATED AS PREDICTORS OF Aβ AMYLOID LOAD IN A BROADER BLOOD-BASED BIOMARKER PANEL 2017 , 13, P1308-P1309		
286	[P4055]: CORTICAL CEREBRAL MICROINFARCTS ON 3T MRI IN ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT 2017 , 13, P1378-P1379		1
285	[P1016]: CSF TOTAL TAU AS A BIOMARKER FOR NEURONAL INJURY IN ALZHEIMER'S DISEASE: ALIGNING RATES OF CSF CHANGE WITH RATES OF HIPPOCAMPAL AND CORTICAL GRAY MATTER ATROPHY 2017 , 13, P436-P436		
284	[P2063]: GRAPHICAL NETWORK ANALYSES INFORMS PET Aβ AMYLOID BIOMARKER DISCOVERY VIA QUANTIFICATION OF INDIVIDUAL PEPTIDE CONNECTIONS 2017 , 13, P714-P714		
283	[P1044]: QUANTITATIVE SUSCEPTIBILITY MAPPING OF THE HIPPOCAMPUS PREDICTS HIPPOCAMPAL ATROPHY IN Aβ ELDERLY CONTROLS AND ALZHEIMER'S DISEASE PATIENTS 2017 , 13, P454-P455		1
282	Cerebral quantitative susceptibility mapping predicts amyloid-β-related cognitive decline. <i>Brain</i> , 2017 , 140, 2112-2119	11.2	144
281	BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. <i>Brain</i> , 2016 , 139, 2766-2777	11.2	48
280	A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2016 , 60, 354-361	3.3	33
279	Predicting Alzheimer disease from a blood-based biomarker profile: A 54-month follow-up. <i>Neurology</i> , 2016 , 87, 1093-101	6.5	23
278	Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. <i>Lancet Neurology, The</i> , 2016 , 15, 1044-53	24.1	135
277	Magnetic Resonance Imaging of Vascular Contributions to Cognitive Impairment and Dementia. <i>Journal of Molecular Neuroscience</i> , 2016 , 60, 349-353	3.3	5
276	Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2016 , 132, 377-89	14.3	30
275	Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's disease. <i>Scientific Reports</i> , 2016 , 6, 29078	4.9	20
274	CapAIBL: Automated Reporting of Cortical PET Quantification Without Need of MRI on Brain Surface Using a Patch-Based Method. <i>Lecture Notes in Computer Science</i> , 2016 , 109-116	0.9	5
273	Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). <i>Lancet Neurology, The</i> , 2016 , 15, 1317-1325	24.1	64
272	The Relationship between Sleep Quality and Brain Amyloid Burden. <i>Sleep</i> , 2016 , 39, 1063-8	1.1	76
271	Rubidium and potassium levels are altered in Alzheimer's disease brain and blood but not in cerebrospinal fluid. <i>Acta Neuropathologica Communications</i> , 2016 , 4, 119	7.3	32
270	Laser ablation-inductively coupled plasma-mass spectrometry imaging of white and gray matter iron distribution in Alzheimer's disease frontal cortex. <i>NeuroImage</i> , 2016 , 137, 124-131	7.9	44

269	Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016 , 2, 19-26	5.2	54
268	Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016 , 3, 18-26	5.2	24
267	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. <i>Annals of Neurology</i> , 2016 , 79, 929-39	9.4	247
266	Amyloid- β Peptide A β P _E -42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons. <i>Journal of Biological Chemistry</i> , 2016 , 291, 6134-45	5.4	63
265	Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016 , 12, 796-804	1.2	102
264	Subjective Memory Complaints in APOE ϵ 4 Carriers are Associated with High Amyloid- β Burden. <i>Journal of Alzheimer's Disease</i> , 2016 , 49, 1115-22	4.3	40
263	High Content, Multi-Parameter Analyses in Buccal Cells to Identify Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2016 , 13, 787-99	3	17
262	Alzheimer's Disease and the Early Signs of Age-Related Macular Degeneration. <i>Current Alzheimer Research</i> , 2016 , 13, 1259-1266	3	32
261	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. <i>Brain</i> , 2016 , 139, 2528-39	11.2	45
260	Impact of Mild Head Injury on Neuropsychological Performance in Healthy Older Adults: Longitudinal Assessment in the AIBL Cohort. <i>Frontiers in Aging Neuroscience</i> , 2016 , 8, 105	5.3	11
259	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. <i>PLoS ONE</i> , 2016 , 11, e0152082	3.7	31
258	P4-388: XANAMEMTM: A Novel 11 β -HSD1 Inhibitor with Potential to Provide Durable Symptomatic and Disease Modifying Benefits in Alzheimer's Disease 2016 , 12, P1186-P1186		1
257	A β -related memory decline in APOE ϵ 4 noncarriers: Implications for Alzheimer disease. <i>Neurology</i> , 2016 , 86, 1635-42	6.5	28
256	Apolipoprotein C-II Adopts Distinct Structures in Complex with Micellar and Submicellar Forms of the Amyloid-Inhibiting Lipid-Mimetic Dodecylphosphocholine. <i>Biophysical Journal</i> , 2016 , 110, 85-94	2.9	2
255	A β Amyloid, APOE and BDNF Genotype, and Depressive and Anxiety Symptoms in Cognitively Normal Older Women and Men. <i>American Journal of Geriatric Psychiatry</i> , 2016 , 24, 1191-1195	6.5	19
254	Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia. <i>Journal of Molecular Neuroscience</i> , 2016 , 60, 362-370	3.3	13
253	The Neurobiology and Age-Related Prevalence of the ϵ 4 Allele of Apolipoprotein E in Alzheimer's Disease Cohorts. <i>Journal of Molecular Neuroscience</i> , 2016 , 60, 316-324	3.3	51
252	High order W02-reactive stable oligomers of amyloid- β are produced in vivo and in vitro via dialysis and filtration of synthetic amyloid- β monomer. <i>Journal of Alzheimer's Disease</i> , 2015 , 44, 69-78	4.3	2

251	Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. <i>Brain</i> , 2015 , 138, 1036-45	11.2	54
250	Stabilization of nontoxic A β oligomers: insights into the mechanism of action of hydroxyquinolines in Alzheimer's disease. <i>Journal of Neuroscience</i> , 2015 , 35, 2871-84	6.6	56
249	Relationships between performance on the Cogstate Brief Battery, neurodegeneration, and A β accumulation in cognitively normal older adults and adults with MCI. <i>Archives of Clinical Neuropsychology</i> , 2015 , 30, 49-58	2.7	35
248	Longitudinal cognitive decline in the AIBL cohort: The role of APOE ϵ status. <i>Neuropsychologia</i> , 2015 , 75, 411-9	3.2	17
247	Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of ageing. <i>Neurobiology of Aging</i> , 2015 , 36, 1231-8	5.6	63
246	Amyloid- β anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study. <i>JAMA Psychiatry</i> , 2015 , 72, 284-91	14.5	114
245	Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. <i>Alzheimer's Research and Therapy</i> , 2015 , 7, 16	9	16
244	Glycosaminoglycan sulfation determines the biochemical properties of prion protein aggregates. <i>Glycobiology</i> , 2015 , 25, 745-55	5.8	10
243	Small angle X-ray scattering analysis of Cu(2+)-induced oligomers of the Alzheimer's amyloid β peptide. <i>Metallomics</i> , 2015 , 7, 536-43	4.5	19
242	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2015 , 85, 790-8	6.5	23
241	Enduring Elevations of Hippocampal Amyloid Precursor Protein and Iron Are Features of β Amyloid Toxicity and Are Mediated by Tau. <i>Neurotherapeutics</i> , 2015 , 12, 862-73	6.4	35
240	Traumatic brain injury induces elevation of Co in the human brain. <i>Metallomics</i> , 2015 , 7, 66-70	4.5	10
239	Tau imaging: early progress and future directions. <i>Lancet Neurology</i> , 2015 , 14, 114-24	24.1	360
238	A β imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 431-6	5.5	63
237	Alpha-synuclein oligomers and fibrils originate in two distinct conformer pools: a small angle X-ray scattering and ensemble optimisation modelling study. <i>Molecular BioSystems</i> , 2015 , 11, 190-6		22
236	Amyloid- β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults. <i>Journal of Alzheimer's Disease</i> , 2015 , 43, 677-86	4.3	54
235	Comparative analysis of the Cancer Council of Victoria and the online Commonwealth Scientific and Industrial Research Organisation FFQ. <i>British Journal of Nutrition</i> , 2015 , 114, 1683-93	3.6	2
234	Alzheimer's disease. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15056	51.1	755

233	Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer's disease. <i>Neuropsychology</i> , 2015 , 29, 571-81	3.8	33
232	Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid- β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Alzheimer's Disease</i> , 2015 , 48, 175-87	4.3	38
231	Buccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkers of Alzheimer's Disease Risk. <i>Journal of Alzheimer's Disease</i> , 2015 , 48, 443-52	4.3	6
230	Peripheral Defensins 1 and 2 are elevated in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 44, 1131-43	4.3	13
229	Alterations in dorsal and ventral posterior cingulate connectivity in APOE 4 carriers at risk of Alzheimer's disease. <i>BJPsych Open</i> , 2015 , 1, 139-148	5	4
228	Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. <i>Journal of Alzheimer's Disease</i> , 2015 , 46, 1079-89	4.3	22
227	A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015 , 7, 50	9	8
226	Alzheimer's disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology. <i>Alzheimer's Research and Therapy</i> , 2015 , 7, 71	9	14
225	Semi-automated hippocampal segmentation in people with cognitive impairment using an age appropriate template for registration. <i>Journal of Magnetic Resonance Imaging</i> , 2015 , 42, 1631-8	5.6	7
224	Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?. <i>Journal of Alzheimer's Disease</i> , 2015 , 47, 815-43	4.3	58
223	Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE ϵ 4 and Is Detectable over 18-Months. <i>PLoS ONE</i> , 2015 , 10, e0139082	3.7	20
222	Factors associated with the onset and persistence of post-lumbar puncture headache. <i>JAMA Neurology</i> , 2015 , 72, 325-32	17.2	43
221	O3-03-04: Characteristics of the neighborhood built environment are associated with MRI brain volumetric and amyloid beta burden measures: Findings from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) study 2015 , 11, P223-P225		
220	Bayesian graphical network analyses reveal complex biological interactions specific to Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 44, 917-25	4.3	10
219	Reduction of p75 neurotrophin receptor ameliorates the cognitive deficits in a model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015 , 36, 740-52	5.6	20
218	Decreased plasma iron in Alzheimer's disease is due to transferrin desaturation. <i>ACS Chemical Neuroscience</i> , 2015 , 6, 398-402	5.7	57
217	APOE ϵ 4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015 , 36, 1239-44	5.6	56
216	Comparison of MR-less PiB SUVR quantification methods. <i>Neurobiology of Aging</i> , 2015 , 36 Suppl 1, S159-66	5.6	70

215	Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. <i>Brain</i> , 2014 , 137, 1762-71	11.2	197
214	Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. <i>Brain</i> , 2014 , 137, 221-31	11.2	145
213	Alzheimer disease: the landscape of ageing--insights from AD imaging markers. <i>Nature Reviews Neurology</i> , 2014 , 10, 678-9	15	9
212	Decreased serum zinc is an effect of ageing and not Alzheimer's disease. <i>Metallomics</i> , 2014 , 6, 1216-9	4.5	31
211	The effect of paraformaldehyde fixation and sucrose cryoprotection on metal concentration in murine neurological tissue. <i>Journal of Analytical Atomic Spectrometry</i> , 2014 , 29, 565-570	3.7	39
210	An iron/dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta. <i>Chemical Science</i> , 2014 , 5, 2160-2169	9.4	82
209	Influence of BDNF Val66Met on the relationship between physical activity and brain volume. <i>Neurology</i> , 2014 , 83, 1345-52	6.5	46
208	In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 816-26	8.8	137
207	Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. <i>Journal of Neuroscience</i> , 2014 , 34, 8021-31	6.6	118
206	Among vitamin B12 deficient older people, high folate levels are associated with worse cognitive function: combined data from three cohorts. <i>Journal of Alzheimer's Disease</i> , 2014 , 39, 661-8	4.3	57
205	Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. <i>Neurology</i> , 2014 , 83, 253-60	6.5	266
204	Genetic heterogeneity in Alzheimer disease and implications for treatment strategies. <i>Current Neurology and Neuroscience Reports</i> , 2014 , 14, 499	6.6	52
203	Brain and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 743-751.e1	1.2	62
202	An increased neutrophil-lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation. <i>Journal of Neuroimmunology</i> , 2014 , 273, 65-71	3.5	46
201	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 53-61	1.2	84
200	Plasma amyloid- β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden. <i>Journal of Alzheimer's Disease</i> , 2014 , 40, 95-104	4.3	34
199	Personal memory function in mild cognitive impairment and subjective memory complaints: results from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Ageing. <i>Journal of Alzheimer's Disease</i> , 2014 , 40, 551-61	4.3	9
198	MR-less surface-based amyloid assessment based on 11C PiB PET. <i>PLoS ONE</i> , 2014 , 9, e84777	3.7	29

197	Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: a preliminary study. <i>PLoS ONE</i> , 2014 , 9, e86498	3.7	57
196	Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations. <i>Frontiers in Neurology</i> , 2014 , 4, 205	4.1	140
195	C-terminal peptides modelling constitutive PrPC processing demonstrate ameliorated toxicity predisposition consequent to β cleavage. <i>Biochemical Journal</i> , 2014 , 459, 103-15	3.8	10
194	Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study. <i>British Journal of Psychiatry</i> , 2014 , 204, 400-1	5.4	22
193	Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. <i>Science Translational Medicine</i> , 2014 , 6, 226ra30	17.5	244
192	Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). <i>International Psychogeriatrics</i> , 2014 , 26, 543-54	3.4	30
191	Incidence of cerebral microbleeds in preclinical Alzheimer disease. <i>Neurology</i> , 2014 , 82, 1266-73	6.5	110
190	Functional connectivity in autosomal dominant and late-onset Alzheimer disease. <i>JAMA Neurology</i> , 2014 , 71, 1111-22	17.2	68
189	Autobiographical narratives relate to Alzheimer's disease biomarkers in older adults. <i>International Psychogeriatrics</i> , 2014 , 26, 1737-46	3.4	4
188	Guanidine hydrochloride denaturation of dopamine-induced β synuclein oligomers: a small-angle X-ray scattering study. <i>Proteins: Structure, Function and Bioinformatics</i> , 2014 , 82, 10-21	4.2	7
187	(18)F-florbetaben A β imaging in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2013 , 5, 4	9	40
186	Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes. <i>Biomarkers in Medicine</i> , 2013 , 7, 641-62	2.3	16
185	Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, E4502-9	11.5	253
184	Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease. <i>BMC Psychology</i> , 2013 , 1, 30	2.8	107
183	Predicting Alzheimer disease with β amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. <i>Annals of Neurology</i> , 2013 , 74, 905-13	9.4	158
182	Profiling the iron, copper and zinc content in primary neuron and astrocyte cultures by rapid online quantitative size exclusion chromatography-inductively coupled plasma-mass spectrometry. <i>Metallomics</i> , 2013 , 5, 1656-62	4.5	35
181	Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2013 , 34, 171-82	4.3	40
180	A β amyloid, cognition, and APOE genotype in healthy older adults. <i>Alzheimer's and Dementia</i> , 2013 , 9, 538-45	1.2	45

179	Research and standardization in Alzheimer's trials: reaching international consensus. <i>Alzheimer's and Dementia</i> , 2013 , 9, 160-8	1.2	16
178	Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. <i>Lancet Neurology</i> , 2013 , 12, 357-67	24.1	1336
177	Mixed ligand Cu^{2+} complexes of a model therapeutic with Alzheimer's amyloid- β peptide and monoamine neurotransmitters. <i>Inorganic Chemistry</i> , 2013 , 52, 4303-18	5.1	51
176	BDNF Val66Met, A β amyloid, and cognitive decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013 , 34, 2457-64	5.6	93
175	Cross-sectional and longitudinal analysis of the relationship between A β deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. <i>JAMA Neurology</i> , 2013 , 70, 903-11	17.2	132
174	Development of a platinum complex as an anti-amyloid agent for the therapy of Alzheimer's disease. <i>Angewandte Chemie - International Edition</i> , 2013 , 52, 3374-8	16.4	44
173	Decline in cognitive function over 18 months in healthy older adults with high amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2013 , 34, 861-71	4.3	34
172	Lack of reliable evidence for a distinctive β -related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study. <i>Brain</i> , 2013 , 136, 2201-16	11.2	24
171	The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study. <i>Neurology</i> , 2013 , 81, 1425-33	6.5	56
170	Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer's disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS). <i>Archives of Clinical Neuropsychology</i> , 2013 , 28, 320-30	2.7	70
169	Head-to-head comparison of ^{11}C -PiB and ^{18}F -AZD4694 (NAV4694) for β amyloid imaging in aging and dementia. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 880-6	8.9	121
168	The association of A β amyloid and composite cognitive measures in healthy older adults and MCI. <i>International Psychogeriatrics</i> , 2013 , 25, 1667-77	3.4	21
167	Cognitive decline in adults with amnesic mild cognitive impairment and high amyloid- β prodromal Alzheimer's disease?. <i>Journal of Alzheimer's Disease</i> , 2013 , 33, 1167-76	4.3	30
166	Cognitive consequences of high A β amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease. <i>Neuropsychology</i> , 2013 , 27, 322-332	3.8	30
165	Development of a Platinum Complex as an anti-Amyloid Agent for the Therapy of Alzheimer's Disease. <i>Angewandte Chemie</i> , 2013 , 125, 3458-3462	3.6	6
164	Rapid decline in episodic memory in healthy older adults with high amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2013 , 33, 675-9	4.3	42
163	Pupil response biomarkers distinguish amyloid precursor protein mutation carriers from non-carriers. <i>Current Alzheimer Research</i> , 2013 , 10, 790-6	3	21
162	Decreased copper in Alzheimer's disease brain is predominantly in the soluble extractable fraction. <i>International Journal of Alzheimer's Disease</i> , 2013 , 2013, 623241	3.7	29

161	Pupil response biomarkers for early detection and monitoring of Alzheimer's disease. <i>Current Alzheimer Research</i> , 2013 , 10, 931-9	3	21
160	Ammonium hydroxide treatment of A β produces an aggregate free solution suitable for biophysical and cell culture characterization. <i>PeerJ</i> , 2013 , 1, e73	3.1	72
159	Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer's disease. <i>Journal of Neuroscience Methods</i> , 2012 , 205, 96-109	3	13
158	Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. <i>Neurology</i> , 2012 , 79, 1645-52	6.5	84
157	Clinical and biomarker changes in dominantly inherited Alzheimer's disease. <i>New England Journal of Medicine</i> , 2012 , 367, 795-804	59.2	2272
156	Blood-based protein biomarkers for diagnosis of Alzheimer disease. <i>Archives of Neurology</i> , 2012 , 69, 1318-25		271
155	Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012 , 34, 345-58	2.1	92
154	The hypoxia imaging agent Cull(atism) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease. <i>Journal of Experimental Medicine</i> , 2012 , 209, 837-54	16.6	113
153	In vitro characterization of [18F]-florbetaben, an A β imaging radiotracer. <i>Nuclear Medicine and Biology</i> , 2012 , 39, 1042-8	2.1	45
152	Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: the AIBL Active trial. <i>BMC Psychiatry</i> , 2012 , 12, 167	4.2	35
151	Utility of an improved model of amyloid-beta (A β) toxicity in <i>Caenorhabditis elegans</i> for drug screening for Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2012 , 7, 57	19	127
150	Variability in blood-based amyloid-beta assays: the need for consensus on pre-analytical processing. <i>Journal of Alzheimer's Disease</i> , 2012 , 30, 323-36	4.3	26
149	Comparison of 11C-PiB and 18F-florbetaben for A β imaging in ageing and Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 983-9	8.8	143
148	The role of metallobiology and amyloid- β peptides in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2012 , 120 Suppl 1, 149-166	6	198
147	The animal models of dementia and Alzheimer's disease for pre-clinical testing and clinical translation. <i>Current Alzheimer Research</i> , 2012 , 9, 1010-29	3	31
146	Relationship between memory performance and β amyloid deposition at different stages of Alzheimer's disease. <i>Neurodegenerative Diseases</i> , 2012 , 10, 141-4	2.3	33
145	Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. <i>Clinical Investigation</i> , 2012 , 2, 975-984		144
144	Regional dynamics of amyloid- β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. <i>Brain</i> , 2012 , 135, 2126-39	11.2	179

143	The prion protein preference of sporadic Creutzfeldt-Jakob disease subtypes. <i>Journal of Biological Chemistry</i> , 2012 , 287, 36465-72	5.4	8
142	Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. <i>Brain</i> , 2011 , 134, 798-807	11.2	113
141	Investigation of matrix metalloproteinases, MMP-2 and MMP-9, in plasma reveals a decrease of MMP-2 in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2011 , 26, 779-86	4.3	36
140	Iatrogenic Creutzfeldt-Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients?. <i>Medical Journal of Australia</i> , 2011 , 194, 214-215	4	
139	Increasing the predictive accuracy of amyloid- β blood-borne biomarkers in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2011 , 24, 47-59	4.3	14
138	The Alzheimer's therapeutic PBT2 promotes amyloid- β degradation and GSK3 phosphorylation via a metal chaperone activity. <i>Journal of Neurochemistry</i> , 2011 , 119, 220-30	6	142
137	Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. <i>Neuropsychologia</i> , 2011 , 49, 2384-90	3.2	126
136	Longitudinal assessment of A β and cognition in aging and Alzheimer disease. <i>Annals of Neurology</i> , 2011 , 69, 181-92	9.4	576
135	Homocysteine, vitamin B12, and folic acid levels in Alzheimer's disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study. <i>Journal of Alzheimer's Disease</i> , 2011 , 27, 909-22	4.3	67
134	Copper promotes the trafficking of the amyloid precursor protein. <i>Journal of Biological Chemistry</i> , 2011 , 286, 8252-8262	5.4	79
133	Crystal structure of the amyloid- β 3 fragment provides a model for oligomer formation in Alzheimer's disease. <i>Journal of Neuroscience</i> , 2011 , 31, 1419-26	6.6	85
132	Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 1210-7	8.9	267
131	Glycosaminoglycan sulphation affects the seeded misfolding of a mutant prion protein. <i>PLoS ONE</i> , 2010 , 5, e12351	3.7	21
130	Larger temporal volume in elderly with high versus low beta-amyloid deposition. <i>Brain</i> , 2010 , 133, 3349-58	11.2	111
129	Iron-export ferroxidase activity of β amyloid precursor protein is inhibited by zinc in Alzheimer's disease. <i>Cell</i> , 2010 , 142, 857-67	56.2	483
128	Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. <i>Neurobiology of Aging</i> , 2010 , 31, 1275-83	5.6	750
127	Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease. <i>Journal of Neuroscience</i> , 2010 , 30, 6315-22	6.6	65
126	Addressing population aging and Alzheimer's disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2010 , 6, 291-6	1.2	36

125	Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. <i>Annals of Neurology</i> , 2010 , 67, 317-24	9.4	255
124	Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. <i>Journal of Alzheimer's Disease</i> , 2010 , 20, 1233-42	4.3	111
123	PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. <i>Journal of Alzheimer's Disease</i> , 2010 , 20, 509-16	4.3	306
122	The structure of dopamine induced alpha-synuclein oligomers. <i>European Biophysics Journal</i> , 2010 , 39, 1407-19	1.9	76
121	Alzheimer's A β peptides with disease-associated N-terminal modifications: influence of isomerisation, truncation and mutation on Cu ²⁺ coordination. <i>PLoS ONE</i> , 2010 , 5, e15875	3.7	35
120	Paradoxical condensation of copper with elevated beta-amyloid in lipid rafts under cellular copper deficiency conditions: implications for Alzheimer disease. <i>Journal of Biological Chemistry</i> , 2009 , 284, 21899-21907	5.4	148
119	The <i>Caenorhabditis elegans</i> A beta 1-42 model of Alzheimer disease predominantly expresses A beta 3-42. <i>Journal of Biological Chemistry</i> , 2009 , 284, 22697-702	5.4	94
118	High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. <i>Archives of Neurology</i> , 2009 , 66, 1537-44		133
117	Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation. <i>Free Radical Biology and Medicine</i> , 2009 , 46, 1328-37	7.8	95
116	Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2009 , 247, 1213-21	3.8	109
115	Restored degradation of the Alzheimer's amyloid-beta peptide by targeting amyloid formation. <i>Journal of Neurochemistry</i> , 2009 , 108, 1198-207	6	77
114	Alanine-2 carbonyl is an oxygen ligand in Cu ²⁺ coordination of Alzheimer's disease amyloid-beta peptide--relevance to N-terminally truncated forms. <i>Journal of the American Chemical Society</i> , 2009 , 131, 8760-1	16.4	154
113	Pleomorphic copper coordination by Alzheimer's disease amyloid-beta peptide. <i>Journal of the American Chemical Society</i> , 2009 , 131, 1195-207	16.4	210
112	Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. <i>Lancet Neurology</i> , 2008 , 7, 129-35	24.1	551
111	Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , 2008 , 7, 779-86	24.1	577
110	Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. <i>Neuron</i> , 2008 , 59, 43-55	13.9	565
109	Mechanisms of A beta mediated neurodegeneration in Alzheimer's disease. <i>International Journal of Biochemistry and Cell Biology</i> , 2008 , 40, 181-98	5.6	198
108	Mouse-adapted sporadic human Creutzfeldt-Jakob disease prions propagate in cell culture. <i>International Journal of Biochemistry and Cell Biology</i> , 2008 , 40, 2793-801	5.6	55

107	Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. <i>NeuroImage</i> , 2008 , 43, 430-9	7.9	70
106	Automated (11)C-PiB standardized uptake value ratio. <i>Academic Radiology</i> , 2008 , 15, 1376-89	4.3	17
105	Cu ²⁺ binding modes of recombinant alpha-synuclein--insights from EPR spectroscopy. <i>Journal of the American Chemical Society</i> , 2008 , 130, 7766-73	16.4	93
104	The ART of loss: Aβ imaging in the evaluation of Alzheimer's disease and other dementias. <i>Molecular Neurobiology</i> , 2008 , 38, 1-15	6.2	81
103	In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. <i>Journal of Neuroscience</i> , 2007 , 27, 10365-71	6.6	130
102	Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. <i>Brain</i> , 2007 , 130, 2837-44	11.2	657
101	Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. <i>Archives of Neurology</i> , 2007 , 64, 1140-4		64
100	Concentration dependent Cu ²⁺ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-beta peptide. <i>Biochemistry</i> , 2007 , 46, 2881-91	3.2	160
99	Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: implications for Alzheimer beta-amyloid pathology. <i>Journal of Inorganic Biochemistry</i> , 2006 , 100, 952-62	4.2	85
98	Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. <i>Journal of Biological Chemistry</i> , 2006 , 281, 17670-80	5.4	222
97	Copper-mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge. <i>Journal of Biological Chemistry</i> , 2006 , 281, 15145-54	5.4	150
96	Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Aβ amyloid pathway. <i>Brain</i> , 2006 , 129, 2823-39	11.2	119
95	Pathways to the discovery of the Aβ amyloid of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2006 , 9, 155-61	4.3	14
94	Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. <i>Journal of Neurochemistry</i> , 2006 , 97, 1700-25	6	190
93	Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease. <i>Aging Cell</i> , 2006 , 5, 69-79	9.9	67
92	Overexpression of Aβ is associated with acceleration of onset of motor impairment and superoxide dismutase 1 aggregation in an amyotrophic lateral sclerosis mouse model. <i>Aging Cell</i> , 2006 , 5, 153-65	9.9	32
91	Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. <i>FASEB Journal</i> , 2005 , 19, 1377-9	0.9	217
90	Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. <i>FASEB Journal</i> , 2004 , 18, 1427-9	0.9	231

89	Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity. <i>Journal of Molecular Biology</i> , 2004 , 340, 1167-83	6.5	179
88	Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. <i>Journal of Biological Chemistry</i> , 2003 , 278, 42959-65	5.4	156
87	Methionine oxidation: Implications for the mechanism of toxicity of the beta-amyloid peptide from Alzheimer's disease. <i>International Journal of Peptide Research and Therapeutics</i> , 2003 , 10, 413-417		13
86	Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. <i>Journal of Neuroscience Research</i> , 2003 , 74, 386-92	4.4	119
85	Methionine oxidation: Implications for the mechanism of toxicity of the beta-amyloid peptide from Alzheimer's disease. <i>International Journal of Peptide Research and Therapeutics</i> , 2003 , 10, 413-417	2.1	3
84	Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. <i>Lancet, The</i> , 2003 , 361, 1258-65	4.0	276
83	Annual Review of Gerontology and Geriatrics, Vol. 21. Vincent J. Cristofalo, Richard Adelman, and K. Warner Schaie (Eds.). New York: Springer Publishing Company, 2002, 296 pp., \$US 58.00 (hardcover).. <i>International Psychogeriatrics</i> , 2002 , 14, 428-429	3.4	
82	Alzheimer's disease amyloid beta and prion protein amyloidogenic peptides promote macrophage survival, DNA synthesis and enhanced proliferative response to CSF-1 (M-CSF). <i>Brain Research</i> , 2002 , 940, 49-54	3.7	16
81	Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H ₂ O ₂ . <i>Journal of Biological Chemistry</i> , 2002 , 277, 40302-8	5.4	472
80	The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. <i>Journal of Neurochemistry</i> , 2001 , 76, 87-96	6	153
79	Interaction of linear homologous DNA duplexes via Holliday junction formation. <i>FEBS Journal</i> , 2001 , 268, 7-14		16
78	The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase. <i>FEBS Journal</i> , 2001 , 268, 5329-36		97
77	Involvement of the 5-lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106-126. <i>Journal of Neuroscience Research</i> , 2001 , 65, 565-72	4.4	43
76	Variable phenotype of Alzheimer's disease with spastic paraparesis. <i>Annals of Neurology</i> , 2001 , 49, 125-9.	4	81
75	Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. <i>Neuron</i> , 2001 , 30, 665-76	13.9	1276
74	Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. <i>Journal of Biological Chemistry</i> , 2001 , 276, 20466-73	5.4	530
73	Henryk M. Wisniewski and the amyloid theory of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2001 , 3, 83-86	4.3	3
72	Crystal Structure of the N-terminal Heparin-Binding Domain of Alzheimer's Amyloid Precursor Protein. <i>Biochemical Society Transactions</i> , 2000 , 28, A447-A447	5.1	

71	A beta peptides and calcium influence secretion of the amyloid protein precursor from chick sympathetic neurons in culture. <i>Journal of Neuroscience Research</i> , 2000 , 61, 449-57	4.4	10
70	Amyloidogenicity and neurotoxicity of peptides corresponding to the helical regions of PrP(C). <i>Journal of Neuroscience Research</i> , 2000 , 62, 293-301	4.4	49
69	Novel Leu723Pro amyloid precursor protein mutation increases amyloid beta42(43) peptide levels and induces apoptosis. <i>Annals of Neurology</i> , 2000 , 47, 249-53	9.4	73
68	Substrate-bound beta-amyloid peptides inhibit cell adhesion and neurite outgrowth in primary neuronal cultures. <i>Journal of Neurochemistry</i> , 2000 , 74, 1122-30	6	43
67	A β peptides and calcium influence secretion of the amyloid protein precursor from chick sympathetic neurons in culture 2000 , 61, 449		1
66	Exacerbation of copper toxicity in primary neuronal cultures depleted of cellular glutathione. <i>Journal of Neurochemistry</i> , 1999 , 72, 2092-8	6	68
65	Intracellular accumulation of detergent-soluble amyloidogenic A beta fragment of Alzheimer's disease precursor protein in the hippocampus of aged transgenic mice. <i>Journal of Neurochemistry</i> , 1999 , 72, 2479-87	6	60
64	Proteolytic fragments of Alzheimer's disease-associated presenilin 1 are present in synaptic organelles and growth cone membranes of rat brain. <i>Journal of Neurochemistry</i> , 1999 , 72, 1564-73	6	47
63	Amyloid Nomenclature Committee. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1999 , 6, 151-2	2.7	1
62	Amyloid precursor protein of Alzheimer's disease: evidence for a stable, full-length, trans-membrane pool in primary neuronal cultures. <i>European Journal of Neuroscience</i> , 1999 , 11, 1779-88 ^{3.5}		18
61	The amyloid beta-protein precursor of Alzheimer's disease is degraded extracellularly by a Kunitz protease inhibitor domain-sensitive trypsin-like serine protease in cultures of chick sympathetic neurons. <i>FEBS Journal</i> , 1999 , 266, 509-16		14
60	Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. <i>Nature Structural Biology</i> , 1999 , 6, 327-31		199
59	The synthesis and spectroscopic analysis of the neurotoxic prion peptide 106-126: Comparative use of manual Boc and Fmoc chemistry. <i>International Journal of Peptide Research and Therapeutics</i> , 1999 , 6, 129-134		
58	The synthesis and spectroscopic analysis of the neurotoxic prion peptide 106-126: Comparative use of manual Boc and Fmoc chemistry. <i>International Journal of Peptide Research and Therapeutics</i> , 1999 , 6, 129-134		9
57	Irregular distribution of cytochrome c oxidase protein subunits in aging and Alzheimer's disease. <i>Annals of Neurology</i> , 1999 , 46, 656-660	9.4	49
56	Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. <i>Annals of Neurology</i> , 1999 , 46, 860-6	9.4	1572
55	Analysis of presenilin 1 and presenilin 2 expression and processing by newly developed monoclonal antibodies. <i>Journal of Neuroscience Research</i> , 1999 , 56, 405-19	4.4	19
54	Familial prion disease mutation alters the secondary structure of recombinant mouse prion protein: implications for the mechanism of prion formation. <i>Biochemistry</i> , 1999 , 38, 3280-4	3.2	34

53	Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. <i>American Journal of Pathology</i> , 1999 , 155, 1173-81	5.8	154
52	Copper inhibits Amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion. <i>Biochemical Journal</i> , 1999 , 344, 461-467	3.8	144
51	The amyloid precursor protein of Alzheimer disease in human brain and blood. <i>Journal of Leukocyte Biology</i> , 1999 , 66, 567-74	6.5	54
50	Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease 1999 , 46, 860		5
49	Effects of the amyloid protein precursor of Alzheimer's disease and other ligands of the LDL receptor-related protein on neurite outgrowth from sympathetic neurons in culture. <i>FEBS Letters</i> , 1998 , 428, 13-6	3.8	24
48	Subcellular localization of the Alzheimer's disease amyloid precursor protein and derived polypeptides expressed in a recombinant yeast system. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1998 , 5, 73-83	2.7	13
47	Copper-binding amyloid precursor protein undergoes a site-specific fragmentation in the reduction of hydrogen peroxide. <i>Biochemistry</i> , 1998 , 37, 7224-30	3.2	120
46	Mutations in the transmembrane domain of APP altering gamma-secretase specificity. <i>Biochemistry</i> , 1997 , 36, 15396-403	3.2	97
45	Expression and analysis of heparin-binding regions of the amyloid precursor protein of Alzheimer's disease. <i>FEBS Letters</i> , 1997 , 415, 303-7	3.8	42
44	Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. <i>Nature Medicine</i> , 1997 , 3, 1016-20	50.5	649
43	Clues to the Etiology of Alzheimer's Disease Through the Study of the Amyloid Precursor Protein. <i>Brain Pathology</i> , 1997 , 7, 1037-1037	6	78
42	Human amyloid precursor-like protein 1--cDNA cloning, ectopic expression in COS-7 cells and identification of soluble forms in the cerebrospinal fluid. <i>FEBS Journal</i> , 1997 , 250, 354-63		49
41	Collection and normal levels of the amyloid precursor protein in plasma. <i>Annals of Neurology</i> , 1997 , 41, 121-4	9.4	17
40	Alzheimer's disease-associated presenilin 1 in neuronal cells: evidence for localization to the endoplasmic reticulum-Golgi intermediate compartment. <i>Journal of Neuroscience Research</i> , 1997 , 49, 719-31	4.4	61
39	Identification of heparin-binding domains in the amyloid precursor protein of Alzheimer's disease by deletion mutagenesis and peptide mapping. <i>Journal of Neurochemistry</i> , 1997 , 68, 1164-72	6	52
38	The amyloid beta-protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells. <i>Journal of Neurochemistry</i> , 1997 , 69, 1177-84	6	94
37	Alzheimer's disease-associated presenilin 1 in neuronal cells: Evidence for localization to the endoplasmic reticulum-Golgi intermediate compartment 1997 , 49, 719		5
36	Rapid cellular uptake of Alzheimer amyloid betaA4 peptide by cultured human neuroblastoma cells. <i>FEBS Letters</i> , 1996 , 394, 174-8	3.8	41

35	Iatrogenic and zoonotic Creutzfeldt-Jakob disease: the Australian perspective. <i>Medical Journal of Australia</i> , 1996 , 164, 598-602	4	14
34	Amyloid, aluminium and the aetiology of Alzheimer's disease. <i>Medical Journal of Australia</i> , 1996 , 164, 383-383	4	1
33	Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. <i>Journal of Biological Chemistry</i> , 1996 , 271, 22908-14	5.4	417
32	A synthetic substrate assay for the gamma-secretase of the beta-A4 amyloid of Alzheimer's disease. <i>Journal of Peptide Science</i> , 1995 , 1, 132-9	2.1	2
31	Amyloid, aluminium and the aetiology of Alzheimer's disease. <i>Medical Journal of Australia</i> , 1995 , 163, 256-9	4	26
30	Gelatinase A possesses a beta-secretase-like activity in cleaving the amyloid protein precursor of Alzheimer's disease. <i>FEBS Letters</i> , 1995 , 377, 267-70	3.8	35
29	The nosology of Creutzfeldt-Jakob disease and conditions related to the accumulation of PrPCJD in the nervous system. <i>Brain Pathology</i> , 1995 , 5, 33-41	6	72
28	Characterization of the high affinity heparin binding site of the Alzheimer's disease beta A4 amyloid precursor protein (APP) and its enhancement by zinc(II). <i>Journal of Molecular Recognition</i> , 1995 , 8, 247-57	2.6	40
27	The beta A4 amyloid precursor protein binding to copper. <i>FEBS Letters</i> , 1994 , 349, 109-16	3.8	206
26	Interaction between the zinc (II) and the heparin binding site of the Alzheimer's disease beta A4 amyloid precursor protein (APP). <i>FEBS Letters</i> , 1994 , 355, 151-4	3.8	75
25	Transforming growth factor beta mediates increase of mature transmembrane amyloid precursor protein in microglial cells. <i>FEBS Letters</i> , 1994 , 342, 267-72	3.8	39
24	Alzheimer's disease: a clearer definition of the genetic components. <i>Medical Journal of Australia</i> , 1994 , 160, 243-244	4	4
23	The role of extracellular matrix in the processing of the amyloid protein precursor of Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> , 1993 , 695, 169-74	6.5	11
22	Expression of L-APP mRNA in brain cells. <i>Annals of the New York Academy of Sciences</i> , 1993 , 695, 183-9	6.5	13
21	Amyloidogenicity of rodent and human beta A4 sequences. <i>FEBS Letters</i> , 1993 , 324, 231-6	3.8	130
20	Human brain beta A4 amyloid protein precursor of Alzheimer's disease: purification and partial characterization. <i>Journal of Neurochemistry</i> , 1992 , 59, 1490-8	6	45
19	An abnormality of plasma amyloid protein precursor in Alzheimer's disease. <i>Annals of Neurology</i> , 1992 , 32, 57-65	9.4	47
18	Amyloid precursor protein (APP) and beta A4 amyloid in the etiology of Alzheimer's disease: precursor-product relationships in the derangement of neuronal function. <i>Brain Pathology</i> , 1991 , 1, 241-51	6	144

17	Human and rodent sequence analogs of Alzheimer's amyloid beta A4 share similar properties and can be solubilized in buffers of pH 7.4. <i>FEBS Journal</i> , 1991 , 201, 61-9		66
16	In-vitro matured human macrophages express Alzheimer's beta A4-amyloid precursor protein indicating synthesis in microglial cells. <i>FEBS Letters</i> , 1991 , 282, 335-40	3.8	44
15	Synthesis and secretion of Alzheimer amyloid beta A4 precursor protein by stimulated human peripheral blood leucocytes. <i>FEBS Letters</i> , 1990 , 277, 261-6	3.8	68
14	Retinoic acid induced differentiated neuroblastoma cells show increased expression of the beta A4 amyloid gene of Alzheimer's disease and an altered splicing pattern. <i>FEBS Letters</i> , 1990 , 269, 305-10	3.8	92
13	The pathology of the amyloid A4 precursor of Alzheimer's disease. <i>Annals of Medicine</i> , 1989 , 21, 89-90	1.5	10
12	Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. <i>Cell</i> , 1989 , 57, 115-26	56.2	1177
11	Rett syndrome: abnormal membrane-bound lamellated inclusions in neurons and oligodendroglia. <i>American Journal of Medical Genetics Part A</i> , 1988 , 29, 365-8		22
10	Neuropathology of unconventional virus infections: molecular pathology of spongiform change and amyloid plaque deposition. <i>Novartis Foundation Symposium</i> , 1988 , 135, 24-36		3
9	The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. <i>Nature</i> , 1987 , 325, 733-6	50.4	4170
8	Neuronal origin of cerebral amyloidogenic proteins: their role in Alzheimer's disease and unconventional virus diseases of the nervous system. <i>Novartis Foundation Symposium</i> , 1987 , 126, 49-64		6
7	Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. <i>Journal of Neurochemistry</i> , 1986 , 46, 1042-5	6	197
6	Rapidly progressive dementia with ataxia. <i>Medical Journal of Australia</i> , 1986 , 144, 24-6, 28	4	1
5	Syndromes of amyotrophic lateral sclerosis and dementia: relation to transmissible Creutzfeldt-Jakob disease. <i>Annals of Neurology</i> , 1983 , 14, 17-26	9.4	128
4	Alzheimer's Disease: Genesis of Amyloid. <i>Novartis Foundation Symposium</i> , 119-131		1
3	Characterization of Brain-Derived Extracellular Vesicle Lipids in Alzheimer's Disease		2
2	Amyloid- β Production 92-96		2
1	Neuroimaging within the Dominantly Inherited Alzheimer's Network (DIAN): PET and MRI		1